TCID Clinical Trials

Size	Price	Qty
10mg	USD 147

Clinical Trials

Several completed clinical trials, including Phase 2 and unphased protocols, have evaluated therapeutic interventions targeting influenza, asthma, and human immunodeficiency virus. These studies examined key outcomes such as prophylactic responses in asthmatic subjects and tissue viral suppression dynamics during viral infection. Research efforts were sponsored and conducted by entities including Visterra Inc., the Biomedical Advanced Research and Development Authority, Hvivo, Prep Biopharm Limited, and the University of California, Los Angeles.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02989194	Completed	Influenza	Visterra Inc.\|Biomedical Advanced Research and Development Authority	2017-01-06	Phase 2
NCT03296917	Completed	Asthma	Hvivo\|Prep Biopharm Limited	2015-12-11	Phase 2
NCT02134431	Completed	Human Immunodeficiency Virus	University of California Los Angeles	2014-05	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the TCID product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

TCID functions as a selective deubiquitinating enzyme inhibitor that directly targets ubiquitin C-terminal hydrolase L3 with an IC50 of 0.6 μM, exhibiting 125-fold selectivity over ubiquitin C-terminal hydrolase L1. By blocking hydrolase-mediated cleavage of ubiquitin conjugates, TCID disrupts downstream proteasomal protein turnover and cellular homeostasis, mitigating pathological cellular mechanisms implicated in clinical trial conditions such as influenza, asthma, and human immunodeficiency virus infection.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).